ସୋଫୋସବୁଭିର/ଭେଲପାଟାସଭିର/ଭୋକ୍ସିଲାପ୍ରେଭିର

ସୋଫୋସବୁଭିର/ଭେଲପାଟାସଭିର/ଭୋକ୍ସିଲାପ୍ରେଭିର
Combination of
Sofosbuvir	NS5B RNA polymerase inhibitor
Velpatasvir	NS5A inhibitor
Voxilaprevir	NS3/4A protease inhibitor
Clinical data
Trade names	Vosevi
AHFS/Drugs.com	monograph
MedlinePlus	a617037
data	US DailyMed: Vosevi;
Pregnancy; category	AU: B1 ; US: N (Not classified yet) ; ;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Chemical and physical data
Formula	C111H135F5N17O26PS
Molar mass	୨,୨୮୧.୪୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C.CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC.CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3;
	InChI InChI=1S/C49H54N8O8.C40H52F4N6O9S.C22H29FN3O9P/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29;1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29;1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61);11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53);5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t27-,28-,38-,39-,41-,42+;20-,22-,23+,26-,27+,28+,30-,39-;14-,16+,18+,20+,22+,36-/m010/s1; Key:FMWRYUBVSONSCK-ZYTFCPLVSA-N;

ସୋଫୋସବୁଭିର/ଭେଲପାଟାସଭିର/ଭୋକ୍ସିଲାପ୍ରେଭିର, ଭୋସେଭି ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ହେପାଟାଇଟିସ ସି ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ମିଶ୍ରଣ ।^[୧] ଏହା ଖାଦ୍ୟ ସହିତ ପାଟିରେ ଦ୍ୱାରା ନିଆଯାଏ । ଏହା ୯୫% ଫଳପ୍ରଦ ।

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ଥକାପଣ, ତରଳ ଝାଡ଼ା, ଶୋଇବାରେ ଅସୁବିଧା ଏବଂ ଅଇ ଲାଗିପାରେ । ^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ହେପାଟାଇଟିସ ବି ପୁନଃ ସକ୍ରିୟ ଏବଂ ଯକୃତ ସମସ୍ୟା ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ । ଗର୍ଭାବସ୍ଥାରେ କ୍ଷତିର କୌଣସି ସ୍ପଷ୍ଟ ପ୍ରମାଣ ନଥିଲେ ମଧ୍ୟ ଏହି ଗୋଷ୍ଠୀରେ ଏହା ଭଲ ଅଧ୍ୟୟନ କରାଯାଇ ନାହିଁ ।^[୩] ଏଥିରେ ସୋଫୋସବୁଭିର/ଭେଲପାଟାସଭିର/ଭୋକ୍ସିଲାପ୍ରେଭିର ଥାଏ ଯାହା ପ୍ରତ୍ୟେକ ଜୀବାଣୁ ଆବଶ୍ୟକ କରୁଥିବା ଏକ ଏନଜାଇମକୁ ଅବରୋଧ କରିଥାଏ ।^[୧]

୩୦୨୭ ମସିହାରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଯୁକ୍ତରାଷ୍ଟ୍ର ଏହି ମିଶ୍ରଣକୁ ଅନୁମୋଦନ କରିଛନ୍ତି ।^[୨]^[୧] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୮ ସପ୍ତାହର ଚିକିତ୍ସା ଖର୍ଚ୍ଚ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୪୮,୫୦୦ ଡଲାର ଥିଲା ।^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୩୦,୦୦୦ ପାଉଣ୍ଡ । ^[୫]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ "Vosevi EPAR". European Medicines Agency (EMA). Archived from the original on 23 October 2020. Retrieved 24 September 2020.
↑ ^୨.୦ ^୨.୧ "Sofosbuvir, Velpatasvir, And Voxilaprevir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 12 January 2020. Retrieved 14 October 2021.
↑ "Sofosbuvir / velpatasvir / voxilaprevir (Vosevi) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 November 2020. Retrieved 14 October 2021.
↑ "Vosevi Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 14 October 2021.
↑ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 667. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[EPAR2021-1] ୧.୦ ^୧.୧ ^୧.୨ "Vosevi EPAR". European Medicines Agency (EMA). Archived from the original on 23 October 2020. Retrieved 24 September 2020.

[AHFS2021-2] ୨.୦ ^୨.୧ "Sofosbuvir, Velpatasvir, And Voxilaprevir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 12 January 2020. Retrieved 14 October 2021.

[Preg2021-3] "Sofosbuvir / velpatasvir / voxilaprevir (Vosevi) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 November 2020. Retrieved 14 October 2021.

[4] "Vosevi Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 14 October 2021.

[BNF80-5] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 667. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[୧]

[୨]

[୩]

[୪]

[୫]